PDCD1 and delirium: Moreover, the last pembrolizumab (anti‐programmed cell death 1 antibody [anti PD‐1]) was given 4 months ago and the possibility of psychiatric disorders including delirium associated with anti PD‐1 is reported to be 1.91% and is the lowest in immune checkpoint inhibitors.4